You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 116 No. 7, July 1981 TABLE OF CONTENTS
  Archives
  •  Online Features
  ORIGINAL ARTICLES
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (27)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Sulfadiazine Silver-Resistant Pseudomonas in Burns

New Topical Agents

Shanta M. Modak, PhD; Charles L. Fox, Jr, MD

Arch Surg. 1981;116(7):854-857.


Abstract

• Sulfadiazine silver—resistant strains of Pseudomonas aeruginosa isolated from burned patients from several countries are sensitive to sulfadiazine silver in vitro, but in burned mice and rats resist topical therapy with sulfadiazine silver. In searching for an effective topical agent against these resistant organisms, we found that FPQC (1-ethyl-6-fluoro-1,4-dihydro-4-oxo-7-[1-piperazinyl]-quinoline-carboxylic acid) and its silver salt are effective both in vitro and in vivo. In vitro, their minimal inhibitory concentrations are ten to 20 times lower than that of sulfadiazine silver. In burned mice infected with resistant Pseudomonas strains, mortality in groups receiving topical therapy with FPQC or FPQC silver is 0%, but 80% to 100% with sulfadiazine silver and 100% without treatment. Similar results were obtained in burned rats. The efficacy of FPQC and FPQC silver in vivo may represent discovery of new agents of known low toxicity that are useful in topical burn therapy.

(Arch Surg 1981;116:854-857)



Author Affiliations

From the Departments of Microbiology and Surgery, Columbia University College of Physicians and Surgeons, New York.


Footnotes

Accepted for publication Jan 29, 1981.

Reprint requests to Department of Surgery, Columbia University College of Physicians and Surgeons, New York, NY 10032 (Dr Modak).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Burn Wound Sepsis
Hansbrough
J Intensive Care Med 1987;2:313-327.
ABSTRACT  

Topical Chlorhexidine Diphosphanilate (WP-973) in Burn Wound Sepsis
McManus et al.
Arch Surg 1984;119:206-211.
ABSTRACT  

Mechanisms of In Vitro Sensitivity to Sulfadiazine Silver
McManus et al.
Arch Surg 1983;118:161-166.
ABSTRACT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1981 American Medical Association. All Rights Reserved.